Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 plus Tislelizumab and Chemotherapy in First-Line Advanced Esophageal Squamous Cell Carcinoma
NCT06010303Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of alcestobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Nov 2023; status: completed.
02
Drugs
alcestobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06010303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010303.